Senolytic

A senolytic (from the words senescence and -lytic, "destroying") is among a class of small molecules under basic research to determine if they can selectively induce death of senescent cells and improve health in humans.[1] A goal of this research is to discover or develop agents to delay, prevent, alleviate, or reverse age-related diseases.[2][3] Removal of senescent cells with senolytics has been proposed as a method of enhancing immunity during aging.[4]

A related concept is "senostatic", which means to suppress senescence.[5]

  1. ^ Childs BG, Durik M, Baker DJ, van Deursen JM (December 2015). "Cellular senescence in aging and age-related disease: from mechanisms to therapy". Nature Medicine. 21 (12): 1424–1435. doi:10.1038/nm.4000. PMC 4748967. PMID 26646499.
  2. ^ Kirkland JL, Tchkonia T (August 2015). "Clinical strategies and animal models for developing senolytic agents". Experimental Gerontology. 68: 19–25. doi:10.1016/j.exger.2014.10.012. PMC 4412760. PMID 25446976.
  3. ^ van Deursen JM (May 2019). "Senolytic therapies for healthy longevity". Science. 364 (6441): 636–637. Bibcode:2019Sci...364..636V. doi:10.1126/science.aaw1299. PMC 6816502. PMID 31097655.
  4. ^ Chambers ES, Akbar AN (2020). "Can blocking inflammation enhance immunity during aging?". The Journal of Allergy and Clinical Immunology. 145 (5): 1323–1331. doi:10.1016/j.jaci.2020.03.016. PMID 32386656.
  5. ^ Hu, Qinchao; Peng, Jianmin; Jiang, Laibo; Li, Wuguo; Su, Qiao; Zhang, Jiayu; Li, Huan; Song, Ming; Cheng, Bin; Xia, Juan; Wu, Tong (28 October 2020). "Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma". Cell Death & Disease. 11 (10): 925. doi:10.1038/s41419-020-03126-0. PMC 7595194. PMID 33116117.